RecensMedical리센스메디컬

RecensMedical's shares have fallen sharply since its March 2026 listing, and the company is loss-making with a large operating deficit on trailing figures.

RecensMedical, a Korean medical and precision device company listed on KOSDAQ on 31 March 2026, closed at ₩6,310 on 23 October 2026, with a market value of about ₩69.4B. On trailing twelve-month figures to H1 2026 it reported revenue of ₩8.8B, an operating loss of ₩10.6B and a net loss of ₩19.1B, with borrowings of ₩5.1B against cash of ₩3.7B. The company profile is not included in the data, so the business description is limited to its sector.

What stands out

• Trailing revenue is ₩8.8B against an operating loss of ₩10.6B, an operating margin of about -120%.
• Free cash flow is negative ₩9.4B over the trailing period, and cash of ₩3.7B sits below borrowings of ₩5.1B.
• The share price is down about 35% over one month and 43% over three months, though it remains well above its 52-week low of ₩5,970.
• Foreign ownership fell from 5.1% to 4.4% over the past 60 days, while institutions were net sellers over the last 20 days and retail investors were net buyers.
• Filings in 2026 include the half-year report, an amended annual report for 2025, and several 5%+ holding reports; no news headlines were in the data.

What to watch

• The next filings and results after the June 2026 half-year report, particularly whether losses narrow and cash burn eases.
• Further 5%+ holding and insider shareholding reports, which could show changes in major shareholders.
• The data does not include a year-end valuation, dividend policy beyond a 0% yield, or any analyst views, so these cannot be assessed from the pack.